{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T09:01:35Z","timestamp":1785488495576,"version":"3.56.0"},"reference-count":113,"publisher":"MDPI AG","issue":"15","license":[{"start":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T00:00:00Z","timestamp":1785456000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA292653"],"award-info":[{"award-number":["R01CA292653"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30CA240139"],"award-info":[{"award-number":["P30CA240139"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"award":["R01CA292653"],"award-info":[{"award-number":["R01CA292653"]}],"id":[{"id":"https:\/\/ror.org\/040gcmg81","id-type":"ROR","asserted-by":"publisher"}]},{"award":["P30CA240139"],"award-info":[{"award-number":["P30CA240139"]}],"id":[{"id":"https:\/\/ror.org\/040gcmg81","id-type":"ROR","asserted-by":"publisher"}]},{"name":"Florida state Department of Health","award":["24B15"],"award-info":[{"award-number":["24B15"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cells"],"abstract":"<jats:p>Kinases are highly explored drug targets due to their central role in cell growth, differentiation, and cell death, as well as their relationship to cancer initiation and progression. However, with more than 500 kinases in the human kinome and significant structural similarities among them, kinases present a major selectivity challenge. Bruton\u2019s tyrosine kinase (BTK), a highly studied kinase, plays an important role in the B-cell receptor pathway. Overexpression of BTK in B cells has been linked to the development of B-cell lymphomas, like chronic lymphocytic leukemia (CLL), as well as certain autoimmune diseases. For this reason, BTK is an attractive therapeutic target. In this review, we will provide a summary of the design of irreversible inhibitors, reversible inhibitors, and Proteolysis-targeting chimera (PROTAC) degraders targeting BTK. We will include crystal structures of compounds bound to BTKWT and provide a review of how the design of these inhibitors and PROTACs leads to a more selective inhibition and degradation of BTK. With the emergence of identified BTK resistance mutations, alternative strategies beyond established BTK inhibitors are fundamental for designing more selective inhibitors and degraders that can overcome resistance.<\/jats:p>","DOI":"10.3390\/cells15151383","type":"journal-article","created":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T08:20:18Z","timestamp":1785486018000},"page":"1383","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Targeting Bruton\u2019s Tyrosine Kinase in CLL: Selectivity, Resistance Mechanisms, and Emerging Therapeutic Strategies"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-8560-287X","authenticated-orcid":false,"suffix":"Jr.","given":"Eduardo","family":"Bravo","sequence":"first","affiliation":[{"name":"Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL 33136, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9748-2020","authenticated-orcid":false,"given":"Claudia Cabrera","family":"Pastrana","sequence":"additional","affiliation":[{"name":"Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL 33136, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2404-5129","authenticated-orcid":false,"given":"Erica N.","family":"Lamkin","sequence":"additional","affiliation":[{"name":"Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL 33136, USA"},{"name":"Medical Scientist Training Program, University of Miami Miller School of Medicine, Miami, FL 33136, USA"},{"name":"Sheila and David Fuente Graduate Program in Cancer Biology, University of Miami Miller School of Medicine, Miami, FL 33136, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katarzyna","family":"Ciurko","sequence":"additional","affiliation":[{"name":"Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL 33136, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4407-6325","authenticated-orcid":false,"given":"Justin","family":"Taylor","sequence":"additional","affiliation":[{"name":"Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL 33136, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,7,31]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/s12943-018-0804-2","article-title":"Kinase-targeted cancer therapies: Progress, challenges and future directions","volume":"17","author":"Bhullar","year":"2018","journal-title":"Mol. Cancer"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2958","DOI":"10.1039\/D5MD00095E","article-title":"Razing the Scaffolding: The Elimination of Non-Catalytic Functions of Kinases through Targeted Protein Degradation","volume":"16","author":"Pogash","year":"2025","journal-title":"RSC Med. Chem."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"e446","DOI":"10.1002\/mco2.446","article-title":"Receptor tyrosine kinases: Biological functions and anticancer targeted therapy","volume":"4","author":"Zhang","year":"2023","journal-title":"MedComm"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"102247","DOI":"10.1016\/j.jbc.2022.102247","article-title":"Structural features of the protein kinase domain and targeted binding by small-molecule inhibitors","volume":"298","author":"Arter","year":"2022","journal-title":"J. Biol. Chem."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1038\/d41573-025-00188-7","article-title":"FDA approves 100th small-molecule kinase inhibitor","volume":"24","author":"Mullard","year":"2025","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.tips.2015.04.005","article-title":"FDA-approved small-molecule kinase inhibitors","volume":"36","author":"Wu","year":"2015","journal-title":"Trends Pharmacol. Sci."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"108107","DOI":"10.1016\/j.phrs.2026.108107","article-title":"Properties of FDA-approved small molecule protein kinase inhibitors: A 2026 update","volume":"224","author":"Roskoski","year":"2026","journal-title":"Pharmacol. Res."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.drudis.2007.03.006","article-title":"Insights for the development of specific kinase inhibitors by targeted structural genomics","volume":"12","author":"Fedorov","year":"2007","journal-title":"Drug Discov. Today"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"15774","DOI":"10.1021\/jacs.8b08048","article-title":"Binding Kinetics Survey of the Drugged Kinome","volume":"140","author":"Georgi","year":"2018","journal-title":"J. Am. Chem. Soc."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/nbt1358","article-title":"A quantitative analysis of kinase inhibitor selectivity","volume":"26","author":"Karaman","year":"2008","journal-title":"Nat. Biotechnol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.tips.2012.03.005","article-title":"Structural approaches to obtain kinase selectivity","volume":"33","author":"Norman","year":"2012","journal-title":"Trends Pharmacol. Sci."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"9776","DOI":"10.1021\/acs.jmedchem.3c01629","article-title":"Overcoming Secondary Mutations of Type II Kinase Inhibitors","volume":"67","author":"Wang","year":"2024","journal-title":"J. Med. Chem."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.tibtech.2008.02.008","article-title":"Turning promiscuous kinase inhibitors into safer drugs","volume":"26","author":"Zhang","year":"2008","journal-title":"Trends Biotechnol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1021\/acs.jmedchem.1c02126","article-title":"New Horizons in Drug Discovery-Understanding and Advancing Different Types of Kinase Inhibitors: Seven Years in Kinase Inhibitor Research with Impressive Achievements and New Future Prospects","volume":"65","author":"Laufer","year":"2022","journal-title":"J. Med. Chem."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/nbt1068","article-title":"A small molecule-kinase interaction map for clinical kinase inhibitors","volume":"23","author":"Fabian","year":"2005","journal-title":"Nat. Biotechnol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1021\/cb500129t","article-title":"Exploration of type II binding mode: A privileged approach for kinase inhibitor focused drug discovery?","volume":"9","author":"Zhao","year":"2014","journal-title":"ACS Chem. Biol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"4312","DOI":"10.1021\/acsptsci.5c00412","article-title":"An Assessment of Kinase Selectivity, Enzyme Inhibition Kinetics and in Vitro Activity for Several Bruton Tyrosine Kinase (BTK) Inhibitors","volume":"8","author":"Corrionero","year":"2025","journal-title":"ACS Pharmacol. Transl. Sci."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1016\/j.cellsig.2010.03.001","article-title":"The Src, Syk, and Tec family kinases: Distinct types of molecular switches","volume":"22","author":"Bradshaw","year":"2010","journal-title":"Cell. Signal."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1007\/s00262-021-02908-5","article-title":"Bruton\u2019s tyrosine kinase: An emerging targeted therapy in myeloid cells within the tumor microenvironment","volume":"70","author":"Good","year":"2021","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1038\/nrc3702","article-title":"Targeting Bruton\u2019s tyrosine kinase in B cell malignancies","volume":"14","author":"Hendriks","year":"2014","journal-title":"Nat. Rev. Cancer"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1358\/dnp.2008.21.7.1255308","article-title":"Bruton\u2019s tyrosine kinase as a drug discovery target","volume":"21","author":"Pan","year":"2008","journal-title":"Drug News Perspect."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"106577","DOI":"10.1016\/j.bioorg.2023.106577","article-title":"Recent research of BTK inhibitors: Methods of structural design, pharmacological activities, manmade derivatives and structure-activity relationship","volume":"138","author":"Wang","year":"2023","journal-title":"Bioorg. Chem."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/S0952-7915(00)00088-1","article-title":"Tec Family Kinases in lymphocyte signaling and function","volume":"12","author":"Schaeffer","year":"2000","journal-title":"Curr. Opin. Immunol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.ejmech.2018.03.062","article-title":"The development of Bruton\u2019s tyrosine kinase (BTK) inhibitors from 2012 to 2017: A mini-review","volume":"151","author":"Liang","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2355","DOI":"10.1111\/all.15261","article-title":"Bruton\u2019s tyrosine kinase inhibition-An emerging therapeutic strategy in immune-mediated dermatological conditions","volume":"77","author":"Brasileiro","year":"2022","journal-title":"Allergy"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1111\/imr.12792","article-title":"Pathogenic B-cell receptor signaling in lymphoid malignancies: New insights to improve treatment","volume":"291","author":"Young","year":"2019","journal-title":"Immunol. Rev."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Satterthwaite, A.B. (2017). Bruton\u2019s Tyrosine Kinase, a Component of B Cell Signaling Pathways, Has Multiple Roles in the Pathogenesis of Lupus. Front. Immunol., 8.","DOI":"10.3389\/fimmu.2017.01986"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s13045-021-01049-7","article-title":"Targeting Bruton tyrosine kinase using non-covalent inhibitors in B cell malignancies","volume":"14","author":"Gu","year":"2021","journal-title":"J. Hematol. Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1038\/s41571-024-00956-1","article-title":"Navigating the changing landscape of BTK-targeted therapies for B cell lymphomas and chronic lymphocytic leukaemia","volume":"21","author":"Stanchina","year":"2024","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1111\/j.1600-065X.2000.imr017504.x","article-title":"The role of Bruton\u2019s tyrosine kinase in B-cell development and function: A genetic perspective","volume":"175","author":"Satterthwaite","year":"2000","journal-title":"Immunol. Rev."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1007\/s40265-021-01592-0","article-title":"Bruton\u2019s Tyrosine Kinase Inhibition as an Emerging Therapy in Systemic Autoimmune Disease","volume":"81","author":"Neys","year":"2021","journal-title":"Drugs"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"6243","DOI":"10.1021\/jm3003203","article-title":"Irreversible protein kinase inhibitors: Balancing the benefits and risks","volume":"55","author":"Barf","year":"2012","journal-title":"J. Med. Chem."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1038\/s41573-021-00195-4","article-title":"Kinase drug discovery 20 years after imatinib: Progress and future directions","volume":"20","author":"Cohen","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/nrd3410","article-title":"The resurgence of covalent drugs","volume":"10","author":"Singh","year":"2011","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"2617","DOI":"10.1039\/C9CS00720B","article-title":"Advances in covalent kinase inhibitors","volume":"49","author":"Abdeldayem","year":"2020","journal-title":"Chem. Soc. Rev."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/j.tips.2026.05.001","article-title":"Remibrutinib (Rhapsido) for chronic spontaneous urticaria","volume":"22","author":"Lamkin","year":"2026","journal-title":"Trends Pharmacol. Sci."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"13075","DOI":"10.1073\/pnas.1004594107","article-title":"The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy","volume":"107","author":"Honigberg","year":"2010","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/j.hoc.2025.05.009","article-title":"Resistance to Bruton Tyrosine Kinase Inhibitors","volume":"39","author":"Brown","year":"2025","journal-title":"Hematol. Oncol. Clin. N. Am."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1021\/jm101396q","article-title":"Cysteine mapping in conformationally distinct kinase nucleotide binding sites: Application to the design of selective covalent inhibitors","volume":"54","author":"Leproult","year":"2011","journal-title":"J. Med. Chem."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1002\/pro.321","article-title":"Structures of human Bruton\u2019s tyrosine kinase in active and inactive conformations suggest a mechanism of activation for TEC family kinases","volume":"19","author":"Marcotte","year":"2010","journal-title":"Protein Sci."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"10513","DOI":"10.1021\/acs.jmedchem.4c01308","article-title":"Covalent Inhibitors: To Infinity and Beyond","volume":"67","author":"Raouf","year":"2024","journal-title":"J. Med. Chem."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"7415","DOI":"10.1021\/acs.jmedchem.2c00030","article-title":"Medicinal Chemistry Strategies for the Development of Bruton\u2019s Tyrosine Kinase Inhibitors against Resistance","volume":"65","author":"Sun","year":"2022","journal-title":"J. Med. Chem."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.jacep.2022.11.034","article-title":"Kinase Inhibitors and Atrial Fibrillation: Mechanisms of Action and Clinical Implications","volume":"9","author":"Potter","year":"2023","journal-title":"JACC Clin. Electrophysiol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1111\/ejh.70047","article-title":"Cardiovascular Challenges in Chronic Lymphocytic Leukemia (CLL) Patients Undergoing Bruton Tyrosine Kinase (BTK) Inhibitor Therapy","volume":"116","author":"Oliva","year":"2026","journal-title":"Eur. J. Haematol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1097\/MBC.0000000000000749","article-title":"Ibrutinib-related bleeding: Pathogenesis, clinical implications and management","volume":"29","author":"Aguilar","year":"2018","journal-title":"Blood Coagul. Fibrinolysis"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1016\/j.jacep.2018.06.004","article-title":"Ibrutinib-Associated Atrial Fibrillation","volume":"4","author":"Ganatra","year":"2018","journal-title":"JACC Clin. Electrophysiol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1016\/j.hrthm.2019.04.008","article-title":"Ibrutinib promotes atrial fibrillation by inducing structural remodeling and calcium dysregulation in the atrium","volume":"16","author":"Jiang","year":"2019","journal-title":"Heart Rhythm"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"101432","DOI":"10.1016\/j.redox.2020.101432","article-title":"Enhanced cardiomyocyte reactive oxygen species signaling promotes ibrutinib-induced atrial fibrillation","volume":"30","author":"Yang","year":"2020","journal-title":"Redox Biol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"28040","DOI":"10.1038\/s41598-025-07756-2","article-title":"In silico analysis of atrial fibrillation and hypertension mechanism of action secondary to ibrutinib\/acalabrutinib in chronic lymphocytic leukemia","volume":"15","author":"Cordoba","year":"2025","journal-title":"Sci. Rep."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"3592","DOI":"10.1182\/blood-2003-04-1142","article-title":"Tec regulates platelet activation by GPVI in the absence of Btk","volume":"102","author":"Atkinson","year":"2003","journal-title":"Blood"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1111\/ejh.13148","article-title":"The effect of Bruton\u2019s tyrosine kinase (BTK) inhibitors on collagen-induced platelet aggregation, BTK, and tyrosine kinase expressed in hepatocellular carcinoma (TEC)","volume":"101","author":"Chen","year":"2018","journal-title":"Eur. J. Haematol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1124\/jpet.117.242909","article-title":"Acalabrutinib (ACP-196): A Covalent Bruton Tyrosine Kinase Inhibitor with a Differentiated Selectivity and In Vivo Potency Profile","volume":"363","author":"Barf","year":"2017","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1038\/s41408-023-00902-x","article-title":"Zanubrutinib: Past, present, and future","volume":"13","author":"Tam","year":"2023","journal-title":"Blood Cancer J."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"2296","DOI":"10.1080\/10428194.2023.2254876","article-title":"Combined analysis of the impact of second-generation BTK inhibitors on patient outcomes","volume":"64","author":"Redd","year":"2023","journal-title":"Leuk. Lymphoma"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"3441","DOI":"10.1200\/JCO.21.01210","article-title":"Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial","volume":"39","author":"Byrd","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1056\/NEJMoa2211582","article-title":"Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia","volume":"388","author":"Brown","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1021\/acs.jmedchem.7b01712","article-title":"Discovery of GDC-0853: A Potent, Selective, and Noncovalent Bruton\u2019s Tyrosine Kinase Inhibitor in Early Clinical Development","volume":"61","author":"Crawford","year":"2018","journal-title":"J. Med. Chem."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1016\/j.bmcl.2015.01.032","article-title":"Potent and selective Bruton\u2019s tyrosine kinase inhibitors: Discovery of GDC-0834","volume":"25","author":"Young","year":"2015","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"9173","DOI":"10.1021\/acs.jmedchem.6b01088","article-title":"Discovery of 6-Fluoro-5-(R)-(3-(S)-(8-fluoro-1-methyl-2,4-dioxo-1,2-dihydroquinazolin-3(4H)-yl)-2-methylphenyl)-2-(S)-(2-hydroxypropan-2-yl)-2,3,4,9-tetrahydro-1H-carbazole-8-carboxamide (BMS-986142): A Reversible Inhibitor of Bruton\u2019s Tyrosine Kinase (BTK) Conformationally Constrained by Two Locked Atropisomers","volume":"59","author":"Watterson","year":"2016","journal-title":"J. Med. Chem."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"7915","DOI":"10.1021\/acs.jmedchem.6b00722","article-title":"Small Molecule Reversible Inhibitors of Bruton\u2019s Tyrosine Kinase (BTK): Structure-Activity Relationships Leading to the Identification of 7-(2-Hydroxypropan-2-yl)-4-[2-methyl-3-(4-oxo-3,4-dihydroquinazolin-3-yl)phenyl]-9H-carbazole-1-carboxamide (BMS-935177)","volume":"59","author":"Shi","year":"2016","journal-title":"J. Med. Chem."},{"key":"ref_61","first-page":"62","article-title":"Preclinical characterization of pirtobrutinib, a highly selective, noncovalent (reversible) BTK inhibitor","volume":"142","author":"Gomez","year":"2023","journal-title":"Blood"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1021\/acs.jmedchem.1c01978","article-title":"Targeting the Non-Catalytic Functions: A New Paradigm for Kinase Drug Discovery?","volume":"65","author":"Wang","year":"2022","journal-title":"J. Med. Chem."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"eadi5798","DOI":"10.1126\/science.adi5798","article-title":"Kinase-impaired BTK mutations are susceptible to clinical-stage BTK and IKZF1\/3 degrader NX-2127","volume":"383","author":"Montoya","year":"2024","journal-title":"Science"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1056\/NEJMoa2114110","article-title":"Mechanisms of Resistance to Noncovalent Bruton\u2019s Tyrosine Kinase Inhibitors","volume":"386","author":"Wang","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.chembiol.2017.09.010","article-title":"Lessons in PROTAC Design from Selective Degradation with a Promiscuous Warhead","volume":"25","author":"Bondeson","year":"2018","journal-title":"Cell Chem. Biol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1021\/acs.jmedchem.9b01456","article-title":"Designing Chimeric Molecules for Drug Discovery by Leveraging Chemical Biology","volume":"63","author":"Borsari","year":"2020","journal-title":"J. Med. Chem."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1038\/s41589-019-0362-y","article-title":"Development of targeted protein degradation therapeutics","volume":"15","author":"Chamberlain","year":"2019","journal-title":"Nat. Chem. Biol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1016\/j.chembiol.2017.05.024","article-title":"Targeted Protein Degradation: From Chemical Biology to Drug Discovery","volume":"24","author":"Cromm","year":"2017","journal-title":"Cell Chem. Biol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1021\/acsmedchemlett.9b00597","article-title":"PROTAC Technology: Opportunities and Challenges","volume":"11","author":"Gao","year":"2020","journal-title":"ACS Med. Chem. Lett."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"109574","DOI":"10.1016\/j.isci.2024.109574","article-title":"Inhibitors to degraders: Changing paradigm in drug discovery","volume":"27","author":"Haridas","year":"2024","journal-title":"iScience"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"2321","DOI":"10.1021\/acs.jmedchem.3c01007","article-title":"Discovery and Preclinical Pharmacology of NX-2127, an Orally Bioavailable Degrader of Bruton\u2019s Tyrosine Kinase with Immunomodulatory Activity for the Treatment of Patients with B Cell Malignancies","volume":"67","author":"Robbins","year":"2024","journal-title":"J. Med. Chem."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.chembiol.2017.09.009","article-title":"The Advantages of Targeted Protein Degradation Over Inhibition: An RTK Case Study","volume":"25","author":"Burslem","year":"2018","journal-title":"Cell Chem. Biol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"4877","DOI":"10.2147\/OTT.S249586","article-title":"Ibrutinib in Chronic Lymphocytic Leukemia: Clinical Applications, Drug Resistance, and Prospects","volume":"13","author":"Zhou","year":"2020","journal-title":"OncoTargets Ther."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1016\/j.chembiol.2019.02.021","article-title":"Leveraging Compound Promiscuity to Identify Targetable Cysteines within the Kinome","volume":"26","author":"Rao","year":"2019","journal-title":"Cell Chem. Biol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"a0000028","DOI":"10.36877\/pmmb.a0000028","article-title":"A review on the potential of Bruton\u2019s tyrosine kinase (Btk) inhibitor\u2013ibrutinib for treatment of multiple myeloma (MM)","volume":"2","author":"Bong","year":"2019","journal-title":"Prog. Microbes Mol. Biol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1124\/mol.116.107037","article-title":"Ability of Bruton\u2019s Tyrosine Kinase Inhibitors to Sequester Y551 and Prevent Phosphorylation Determines Potency for Inhibition of Fc Receptor but not B-Cell Receptor Signaling","volume":"91","author":"Bender","year":"2017","journal-title":"Mol. Pharmacol."},{"key":"ref_77","doi-asserted-by":"crossref","unstructured":"Lin, D.Y., and Andreotti, A.H. (2023). Structure of BTK kinase domain with the second-generation inhibitors acalabrutinib and tirabrutinib. PLoS ONE, 18.","DOI":"10.1371\/journal.pone.0290872"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"7923","DOI":"10.1021\/acs.jmedchem.9b00687","article-title":"Discovery of Zanubrutinib (BGB-3111), a Novel, Potent, and Selective Covalent Inhibitor of Bruton\u2019s Tyrosine Kinase","volume":"62","author":"Guo","year":"2019","journal-title":"J. Med. Chem."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1182\/blood-2018-99-109973","article-title":"Potency and Selectivity of BTK Inhibitors in Clinical Development for B-Cell Malignancies","volume":"132","author":"Kaptein","year":"2018","journal-title":"Blood"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"129531","DOI":"10.1016\/j.bbagen.2020.129531","article-title":"Biochemical characterization of tirabrutinib and other irreversible inhibitors of Bruton\u2019s tyrosine kinase reveals differences in on- and off-target inhibition","volume":"1864","author":"Liclican","year":"2020","journal-title":"Biochim. Biophys. Acta Gen. Subj."},{"key":"ref_81","doi-asserted-by":"crossref","unstructured":"Abbas, H.A., and Wierda, W.G. (2021). Acalabrutinib: A Selective Bruton Tyrosine Kinase Inhibitor for the Treatment of B-Cell Malignancies. Front. Oncol., 11.","DOI":"10.3389\/fonc.2021.668162"},{"key":"ref_82","doi-asserted-by":"crossref","unstructured":"Salvaris, R.T., Brennan, J., and Lewis, K.L. (2025). BTK Is the Target That Keeps on Giving: A Review of BTK-Degrader Drug Development, Clinical Data, and Future Directions in CLL. Cancers, 17.","DOI":"10.3390\/cancers17030557"},{"key":"ref_83","doi-asserted-by":"crossref","unstructured":"Zhang, D., Gong, H., and Meng, F. (2021). Recent Advances in BTK Inhibitors for the Treatment of Inflammatory and Autoimmune Diseases. Molecules, 26.","DOI":"10.3390\/molecules26164907"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"127390","DOI":"10.1016\/j.bmcl.2020.127390","article-title":"Potent, non-covalent reversible BTK inhibitors with 8-amino-imidazo[1,5-a]pyrazine core featuring 3-position bicyclic ring substitutes","volume":"30","author":"Liu","year":"2020","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"103367","DOI":"10.1016\/j.bioorg.2019.103367","article-title":"Design and synthesis of novel 1-substituted 3-(6-phenoxypyridin-3-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine analogs as selective BTK inhibitors for the treatment of mantle cell lymphoma","volume":"94","author":"Ran","year":"2020","journal-title":"Bioorg. Chem."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/nchembio.481","article-title":"Specific Btk inhibition suppresses B cell- and myeloid cell-mediated arthritis","volume":"7","author":"Huang","year":"2011","journal-title":"Nat. Chem. Biol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1021\/acsmedchemlett.7b00103","article-title":"Discovery of Potent and Selective Tricyclic Inhibitors of Bruton\u2019s Tyrosine Kinase with Improved Druglike Properties","volume":"8","author":"Wang","year":"2017","journal-title":"ACS Med. Chem. Lett."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1038\/nchembio799","article-title":"Rational design of inhibitors that bind to inactive kinase conformations","volume":"2","author":"Liu","year":"2006","journal-title":"Nat. Chem. Biol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1056\/NEJMoa2300696","article-title":"Pirtobrutinib after a Covalent BTK Inhibitor in Chronic Lymphocytic Leukemia","volume":"389","author":"Mato","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"eabg5216","DOI":"10.1126\/scisignal.abg5216","article-title":"Kinase-deficient BTK mutants confer ibrutinib resistance through activation of the kinase HCK","volume":"15","author":"Dhami","year":"2022","journal-title":"Sci. Signal."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"A025","DOI":"10.1158\/2643-3249.LYMPHOMA26-A025","article-title":"Abstract A025: CFON-026, a novel macrocyclic BTK inhibitor disrupts scaffold-dependent signaling and overcomes resistance to BTK-directed therapies","volume":"7","author":"Lamkin","year":"2026","journal-title":"Blood Cancer Discov."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1182\/blood-2025-2102","article-title":"Molecular and structural basis of pan-resistance to BTK targeting therapies via BTK A428D mutation","volume":"146","author":"Sievers","year":"2025","journal-title":"Blood"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"7454","DOI":"10.1021\/acs.jmedchem.3c00176","article-title":"Discovery of Novel Bruton\u2019s Tyrosine Kinase PROTACs with Enhanced Selectivity and Cellular Efficacy","volume":"66","author":"Li","year":"2023","journal-title":"J. Med. Chem."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"126877","DOI":"10.1016\/j.bmcl.2019.126877","article-title":"Design, synthesis and biological evaluation of Proteolysis Targeting Chimeras (PROTACs) as a BTK degraders with improved pharmacokinetic properties","volume":"30","author":"Buhimschi","year":"2020","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"7133","DOI":"10.1038\/s41467-022-34807-3","article-title":"DeepPROTACs is a deep learning-based targeted degradation predictor for PROTACs","volume":"13","author":"Li","year":"2022","journal-title":"Nat. Commun."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1182\/blood-2025-86","article-title":"Bexobrutideg (NX-5948), a novel Bruton\u2019s tyrosine kinase (BTK) degrader, demonstrates rapid and durable clinical responses in Relapsed\/Refractory chronic lymphocytic leukemia (CLL): New and updated findings from an ongoing Phase 1a\/b trial","volume":"146","author":"Omer","year":"2025","journal-title":"Blood"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"3895","DOI":"10.1182\/blood-2025-3895","article-title":"Preliminary efficacy and safety of the Bruton tyrosine kinase degrader BGB-16673 in patients with relapsed\/refractory Richter transformation: Results from the ongoing phase 1 CaDAnCe-101 study","volume":"146","author":"Thompson","year":"2025","journal-title":"Blood"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1182\/bloodadvances.2022008121","article-title":"Orally bioavailable BTK PROTAC active against wild-type and C481 mutant BTKs in human lymphoma CDX mouse models","volume":"7","author":"Lim","year":"2023","journal-title":"Blood Adv."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1158\/1538-7445.AM2024-1960","article-title":"Abstract 1960: CFON-026 is a potent non-covalent BTK inhibitor suitable for combination therapy with covalent BTK inhibitors for early eradication of resistance mutations","volume":"84","author":"Muller","year":"2024","journal-title":"Cancer Res."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"5377","DOI":"10.1021\/acs.jmedchem.3c00134","article-title":"Macrocycles in Drug Discovery horizontal line Learning from the Past for the Future","volume":"66","author":"Poongavanam","year":"2023","journal-title":"J. Med. Chem."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"15260","DOI":"10.1021\/acs.jmedchem.4c02886","article-title":"Macrocycles for Conventionally Druggable Targets: Lessons from Macrocyclic Kinase Inhibitors","volume":"68","author":"Whitty","year":"2025","journal-title":"J. Med. Chem."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"2681","DOI":"10.1021\/jm901443h","article-title":"Through the \u201cgatekeeper door\u201d: Exploiting the active kinase conformation","volume":"53","author":"Zuccotto","year":"2010","journal-title":"J. Med. Chem."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"e60470","DOI":"10.7554\/eLife.60470","article-title":"Differential impact of BTK active site inhibitors on the conformational state of full-length BTK","volume":"9","author":"Joseph","year":"2020","journal-title":"eLife"},{"key":"ref_104","doi-asserted-by":"crossref","unstructured":"Issa, I.I., Due, H., Brondum, R.F., Veeravakaran, V., Haraldsdottir, H., Sylvester, C., Brogaard, A., Dhanjal, S., Schmierer, B., and Dybkaer, K. (2024). CRISPR-Cas9 Knockout Screens Identify DNA Damage Response Pathways and BTK as Essential for Cisplatin Response in Diffuse Large B-Cell Lymphoma. Cancers, 16.","DOI":"10.3390\/cancers16132437"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1038\/s41375-024-02317-4","article-title":"Mutation in Bruton Tyrosine Kinase (BTK) A428D confers resistance To BTK-degrader therapy in chronic lymphocytic leukemia","volume":"38","author":"Wong","year":"2024","journal-title":"Leukemia"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1021\/acschembio.3c00803","article-title":"DNA-Encoded Library Technology horizontal line A Catalyst for Covalent Ligand Discovery","volume":"19","author":"Dickson","year":"2024","journal-title":"ACS Chem. Biol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.1021\/acs.jmedchem.3c02070","article-title":"Fragment-to-Lead Medicinal Chemistry Publications in 2022","volume":"67","author":"Woodhead","year":"2024","journal-title":"J. Med. Chem."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"5000","DOI":"10.1021\/acs.jmedchem.5c00424","article-title":"Fragment-Based Drug Design: From Then until Now, and Toward the Future","volume":"68","author":"Xu","year":"2025","journal-title":"J. Med. Chem."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"19521","DOI":"10.1021\/acs.jmedchem.5c01742","article-title":"Exploiting Avidity Effects for the Discovery of Low Affinity Protein-Binding Fragments","volume":"68","author":"Jayalath","year":"2025","journal-title":"J. Med. Chem."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1021\/acsptsci.1c00118","article-title":"DNA-Encoded Chemical Libraries: A Comprehensive Review with Succesful Stories and Future Challenges","volume":"4","author":"Donckele","year":"2021","journal-title":"ACS Pharmacol. Transl. Sci."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"4259","DOI":"10.1080\/07391102.2025.2502140","article-title":"Computational insights into mutation-induced binding changes in Bruton\u2019s Tyrosine Kinase with non-covalent inhibitors","volume":"44","author":"Mallen","year":"2025","journal-title":"J. Biomol. Struct. Dyn."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"14580","DOI":"10.1021\/acs.jmedchem.6c00527","article-title":"Linker-Driven Sampling of PROTAC-Induced Ternary Complexes","volume":"69","author":"Zhao","year":"2026","journal-title":"J. Med. Chem."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1080\/17460441.2025.2458666","article-title":"Virtual screening: Hope, hype, and the fine line in between","volume":"20","author":"Nada","year":"2025","journal-title":"Expert Opin. Drug Discov."}],"container-title":["Cells"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4409\/15\/15\/1383\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T08:36:08Z","timestamp":1785486968000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4409\/15\/15\/1383"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,31]]},"references-count":113,"journal-issue":{"issue":"15","published-online":{"date-parts":[[2026,8]]}},"alternative-id":["cells15151383"],"URL":"https:\/\/doi.org\/10.3390\/cells15151383","relation":{},"ISSN":["2073-4409"],"issn-type":[{"value":"2073-4409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,31]]}}}